Repetitive Monomorphic Ventricular Tachycardia (RMVT)

Repetitive monomorphic ventricular tachycardia (RMVT) is an uncommon type of ventricular tachycardia that tends to occur in young people whose hearts are otherwise normal. This is in stark contrast to the usual kind of ventricular tachycardia, which is most often seen in older people who have coronary artery disease or heart failure.

A woman with her head in her hands and a blurred background suggesting dizziness

Pornpak Khunatorn / Getty Images

What Is Ventricular Tachycardia?

Ventricular tachycardia is a sudden, rapid, often dangerous cardiac arrhythmia that originates in the cardiac ventricles. While sometimes a person having ventricular tachycardia will experience only minimal symptoms, much more typically this arrhythmia causes immediate problems which may include significant palpitations, severe lightheadedness, syncope (loss of consciousness), or even cardiac arrest and sudden death.

These symptoms occur because ventricular tachycardia disrupts the heart's ability to pump effectively. The pumping action of the heart deteriorates during ventricular tachycardia for two reasons. First, the heart rate during this arrhythmia tends to be very rapid (often, greater than 180 or 200 beats per minute), rapid enough to reduce the volume of blood the heart can pump. Second, ventricular tachycardia can disrupt the normal, orderly, coordinated contraction of the heart muscle — so much of the work the heart is able to do becomes wasted. These two factors together often make ventricular tachycardia a particularly dangerous cardiac arrhythmia.

What Makes RMVT Distinctive

Three things make RMVT different from "typical" ventricular tachycardia: who gets is, what causes it, and how it is treated.

Typical ventricular tachycardia is an arrhythmia that occurs in older people who have underlying heart disease. The diseased cardiac muscle creates a localized environment in which ventricular tachycardia occurs.

In contrast, RMVT is seen almost exclusively in people under 40 or 45 years of age who have structurally normal hearts, and it seems to be especially prominent in athletes. Some experts have speculated that many non-athletes who are born with the propensity for RMVT simply never produce the high levels of physical stress that are sometimes needed to trigger these arrhythmias. While an underlying genetic cause seems likely, this has not been proven.

Typical ventricular tachycardia is a reentrant arrhythmia. RMVT, on the other hand, is not a reentrant arrhythmia but is caused by an entirely different mechanism (so-called "triggered" activity), that is related to an abnormal flow of ions across the cardiac cell membrane.

Because of the differences in who gets these arrhythmias and how they occur, the treatment of RMVT is much different from the treatment of typical ventricular tachycardia. More on the treatment below.


RMVT usually produces frequent, brief, non-sustained "bursts" of ventricular tachycardia, though it is also common for people with this condition to have occasional longer episodes.

The most common symptoms caused by RMVT are palpitations and dizziness. More rarely, syncope (loss of consciousness) can also occur. Fortunately, the risk of cardiac arrest and sudden death with RMVT appears to be quite low.

The ventricular tachycardia associated with RMVT can be triggered by situations in which adrenalin levels are elevated. So, people with RMVT are most likely to experience symptoms with exercise (in particular, during the warm-down period immediately following exercise), or during periods of severe emotional stress. In fact, stress testing — which will often reproduce the arrhythmia — is a reliable way of diagnosing RMVT.


Treatment of RMVT can be accomplished either with medical therapy or with ablation therapyImplantable defibrillators are only rarely appropriate in RMVT since the risk of sudden death is low.

Fortunately, RMVT can often be controlled with a calcium blocker (verapamil) or with beta blockers (such as propranolol) — drugs that tend to produce relatively few side effects.

If these drugs do not provide sufficient suppression of ventricular tachycardia, the use of more powerful antiarrhythmic drugs can be considered, although these drugs tend to cause much more toxicity.

In most patients with RMVT, the ventricular tachycardia originates in a localized area in the upper portion of the right ventricle, just below the pulmonic valve. In a few patients who have RMVT, the arrhythmia comes from a similar location in the left ventricle — that is, just below the aortic valve.

In either case, the fact that the arrhythmia's origin can be isolated to a particular location makes RMVT amenable to ablation therapy. Successful ablation of RMVT can be achieved in more than 90% of patients with this condition.

Given these treatment options, most experts will first attempt to treat a patient with RMVT using verapamil and/or a beta blocker. If that is not successful, ablation therapy is usually considered to be the next step. One way or the other, with good medical care the arrhythmias associated with RMVT can usually be controlled or eliminated.

A Word From Verywell

RMVT is a particular type of ventricular tachycardia seen in otherwise healthy young people — particularly in athletes. While the risk of death from RMVT appears to be quite low, this arrhythmia can be disruptive to a person’s life. Fortunately, with appropriate therapy, it can be controlled or eliminated.

Was this page helpful?
Article Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2018; 72:e91. DOI:10.1016/j.jacc.2017.10.054

  2. Lemery R, Brugada P, Bella PD, et al. Nonischemic ventricular tachycardia. Clinical course and long-term follow-up in patients without clinically overt heart disease. Circulation 1989; 79:990. DOI:10.1161/01.cir.79.5.990

  3. Kim RJ, Iwai S, Markowitz SM, et al. Clinical and electrophysiological spectrum of idiopathic ventricular outflow tract arrhythmias. J Am Coll Cardiol 2007; 49:2035. DOI:10.1016/j.jacc.2007.01.085

  4. Movsowitz C, Schwartzman D, Callans DJ, et al. Idiopathic right ventricular outflow tract tachycardia: narrowing the anatomic location for successful ablation. Am Heart J 1996; 131:930. DOI:10.1016/s0002-8703(96)90175-1

Additional Reading
  • Fogoros RN, Mandrola JM. Ablation of PVCs and Ventricular Tachycardia. In: Fogoros’ Electrophysiologic Testing, 6th, John Wiley & Sons, Oxford, 2017.